Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma Table 1. Comparison of Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback